IRCT20200204046377N1招募中3 期
Efficacy and safety of Aprepitant in prevention of chemotherapy induced nausea and vomiting in oncologic patients of Mofid children’s hospital
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 months 至 17 years（—）
- 性别
- All
入选标准
- •age between 6 month to 17 years
- •Proven malignancy
- •Chemotherapy regimen with moderate to severe nausea
- •Lack of nausea and vomiting 24 hours before starting chemotherapy
- •Lack of known long QT syndrome
- •Lack of abdominal and pelvic radiation therapy over the past week
- •No active infection or any uncontrolled disease associated with malignancy
- •Absence of corticosteroids starting 72 hours prior to chemotherapy for any reason
- •Lack of Benzodiazepine or opioid for 48 hours
排除标准
- •Sensitivity to the drugs used
- •Dissatisfaction
研究者
相似试验
已完成
3 期
The safety and efficacy of Aprepitant to the prevention of chemotherapy-induced nausea and vomitingIRCT20200819048455N1Iran University of Medical Sciences85
招募中
不适用
Efficacy and safety of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with hematological malignancies after highly emetogenic chemotherapyhematological malignanciesJPRN-UMIN000005624Tokushima University Hospital100
招募中
1 期
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting after bariatric surgery.Postoperative nausea and vomitingCTIS2023-508849-40-00niversity Of Tartu260
进行中（未招募）
不适用
Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer - EMEND_GIChemotherapy-induced nasuea and vomiting (CINV)EUCTR2004-003783-30-DETechnical Unversity of Munich
进行中（未招募）
1 期
Aprepitant – effect and safety in treatment of atopic dermatitisAtopic DermatitisEUCTR2013-002029-40-SEKarolinska Institutet50